Boardroom Alpha
Meeting calendar
VRRM · Annual meeting · Tuesday, May 19, 2026

Verra Mobility Corp

3 nominees · 4 ballot items.

Elect three Class II directors; advisory say-on-pay to approve executive compensation; advisory vote on frequency of future say-on-pay votes (board recommends annual); and ratification of Deloitte & Touche LLP as independent registered public accounting firm.

Market cap
$626M
1Y TSR
-82.6%
Board grade
C-
Record date
Mar 24, 2026
Filing
DEF 14A
Meeting concluded · May 19, 2026

Follow how the vote landed and what changed on Verra Mobility Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot4

  1. 1

    Election of Class II Directors

    ManagementBoard: FOR

    Elect three Class II directors — Patrick J. Byrne, David M. Roberts, and John H. Rexford — to serve until the 2029 annual meeting.

  2. 2

    Advisory Vote to Approve Executive Compensation

    ManagementBoard: FOR

    Non-binding advisory vote to approve, on an advisory basis, the compensation of the named executive officers as disclosed in the proxy statement (say-on-pay).

    More detail

    This is a management-sponsored, non-binding “say-on-pay” proposal asking stockholders to approve the Company’s executive compensation disclosure and overall compensation program for the named executive officers as presented in the proxy statement. Management frames the program as pay-for-performance, emphasizing a mix of base salary, an Annual Incentive Plan tied to revenue and Adjusted EBITDA, and long-term incentives weighted toward performance share units (PSUs) tied to relative TSR and a five-year LTIP with absolute TSR hurdles. The Board seeks a stockholder endorsement to validate its compensation design and to signal alignment between management pay and stockholder interests; it notes strong prior support (approximately 94.6% in 2025). The proposal is advisory and non-binding, so while the Board will consider the outcome when setting future pay practices, it is not obliged to change compensation structures solely based on the vote. Key governance context includes use of an independent compensation consultant, robust performance metrics, clawback policy, stock ownership guidelines, and significant at‑risk pay (majority variable for the CEO). Risks for investors include potential for misalignment if performance metrics or comparator groups (S&P 1000 for PSUs) are not appropriate, and that the non-binding nature limits direct corrective power. A vote FOR would signal shareholder support for the Board’s pay philosophy and incentive structures; a vote AGAINST could prompt more shareholder engagement and potential adjustments to target-setting, mix of PSUs vs RSUs, or the comparator group. The Board’s recommendation is grounded in the Committee’s view that the program rewards sustained long-term performance while providing retention incentives through multi-year awards.

  3. 3

    Advisory Vote on Frequency of Say-on-Pay Vote

    ManagementBoard: FOR

    Non-binding advisory vote to select whether future advisory votes to approve executive compensation should occur every 1, 2, or 3 years (Board recommends 1 year).

    More detail

    This management proposal presents stockholders with a non-binding choice among holding the advisory say-on-pay vote every one, two, or three years; the Board recommends annual votes. The proposal asks only for a preference on frequency, not approval of compensation itself, and the option receiving the plurality of votes will be considered the shareholder preference. Management argues that annual votes provide timely, regular opportunities for shareholders to express views on executive pay and enable ongoing engagement and responsiveness to governance concerns. The non-binding nature means the Board retains discretion and could adopt a different cadence if it believes that is in stockholders’ best interests, but a decisive shareholder preference can shape Board practice and signal governance expectations. From a governance perspective, annual votes are often favored where pay programs are complex or where frequent shareholder feedback is desired; multi-year votes are sometimes proposed to reduce administrative burden and encourage long-term focus. Investors should weigh the benefits of frequent accountability against potential short-termism incentives; however, because the vote is purely advisory, its practical impact depends on how the Board responds to the outcome. The Board’s recommendation for annual voting is consistent with its stated intent to engage in ongoing dialogue on compensation and to consider shareholder feedback when setting compensation practices.

  4. 4

    Ratification of Selection of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026.

Director elections

Nominees on the ballot3

Independent
Tenure on this board
5.7 yrs
Also a director at
Diebold Nixdorf Inc (DBD)Gxo Logistics Inc (GXO)
Not independent
Tenure on this board
7.6 yrs
Also a director at
Hni Corp (HNI)
Ownership

Top institutional holders10

Latest 13F quarter
1BlackRock, Inc.11.0%16,720,158$239M
2PRICE T ROWE ASSOCIATES INC /MD/6.2%9,351,111$134M
3VANGUARD PORTFOLIO MANAGEMENT LLC5.4%8,270,516$118M
4VANGUARD CAPITAL MANAGEMENT LLC4.4%6,633,759$95M
5STATE STREET CORP4.1%6,199,602$89M
6BANK OF MONTREAL /CAN/3.8%5,779,058$83M
7WELLINGTON MANAGEMENT GROUP LLP3.2%4,906,814$70M
8BlackRock, Inc.3.2%4,890,228$70M
9WESTWOOD HOLDINGS GROUP INC3.0%4,499,500$64M
10SNYDER CAPITAL MANAGEMENT L P2.5%3,820,007$55M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Verra Mobility Corp 2026 annual meeting?
Verra Mobility Corp (VRRM) holds its 2026 annual shareholder meeting on Tuesday, May 19, 2026.
What is the record date for the Verra Mobility Corp 2026 meeting?
The record date for the Verra Mobility Corp 2026 meeting is Tuesday, March 24, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Verra Mobility Corp's 2026 meeting?
The board is presenting 3 director nominees at the Verra Mobility Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Verra Mobility Corp 2026 meeting?
Shareholders will vote on 4 proposals at the Verra Mobility Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer